We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Safety Alert on Ariad’s Cancer Drug, Citing Adverse Events
FDA Issues Safety Alert on Ariad’s Cancer Drug, Citing Adverse Events
October 11, 2013
The FDA issued a drug safety alert Oct. 11 for Ariad’s cancer drug Iclusig after one-fifth of patients in a postmarket clinical trial were found to have developed blood clots and narrowing of blood vessels that puts them at higher risk for heart attacks and strokes.